Compare Neurocrine Biosciences Inc (NBIX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Union Pacific Corporation — how do they compare? Neurocrine Biosciences Inc trades at $143.25 (market cap $14.36B), while Union Pacific Corporation trades at $278 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 11.5× Neurocrine Biosciences Inc's market cap, and Union Pacific Corporation pays a 2.04% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Union Pacific Corporation for 105 Days on average.
| NBIX | UNP | |
|---|---|---|
Market Cap | $14.36B | $165.27B |
Volume | 1,237,180 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $185.50 | $310.62 |
52-Week Low | $123.10 | $216.37 |
Typical Hold Time | 23 Days | 105 Days |
Enterprise Value | $14.37B | $194.33B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Union Pacific (UNP) trades at $277.51, up 1.03% with a bullish technical signal and strong fundamental performance. The stock shows robust profitability with 28.85% net margins and 39.7% ROE, supported by consecutive earnings beats in Q1 and Q2 2026. Recent developments include the deployment of battery-electric locomotives and progress on the Norfolk Southern combination, while analyst consensus remains strongly positive with a $332.10 price target.
UNP presents a compelling investment case with strong operational execution and pricing power, though merger uncertainty and fuel cost pressures pose near-term risks. The stock's current valuation at 22.53 P/E offers reasonable upside to analyst targets, supported by consistent dividend payments and infrastructure advantages in the irreplaceable freight rail network.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
